About this medicine

The older licence term “manic-depressive psychosis” refers here to bipolar illness; it is not evidence that the names describe unrelated diseases.

Carbamazepine links neurology and psychiatry: the clinical aim might be seizure control, prevention of mood episodes or relief of trigeminal neuralgia. Those aims require different assessment and dosing. The fact that the ingredient is the same does not make every diagnosis or formulation interchangeable.

What is this medicine used for?

Its psychiatric licence is prophylaxis after inadequate lithium response. This does not automatically license every acute-mania or other psychiatric use.

Prevention means reducing the risk of future episodes, not necessarily treating an acute episode in progress. The UK licence's lithium-response restriction should remain visible. For epilepsy, the product is useful for specified seizure types but can be ineffective or aggravating in others; it is not a medicine for every seizure syndrome.

Which warning signs need help?

Seek urgent assessment for a blistering rash, mouth ulcers, fever, sore throat, unusual bruising or jaundice. Serious skin, blood and liver reactions require rapid recognition.

Low sodium can cause confusion or worsening seizures and deserves assessment. Serious rash is particularly important early in treatment, but a negative genetic screen does not make a new blistering or systemic rash safe to ignore.

How do I take it safely?

For bipolar prophylaxis the label describes starting at 400 mg daily in divided doses, increasing gradually; usual maintenance is 400–600 mg daily. Individual requirements differ.

The liquid contains 100 mg in 5 mL and must be shaken. It can produce higher peaks than the same milligram tablet dose, so a clinician may prescribe smaller, more frequent doses. The liquid has a 1,200 mg daily ceiling in the current label; higher requirements must use a suitable alternative formulation rather than extra liquid.

What side effects should I know about?

Sleepiness, dizziness, dry mouth and nausea are recognised effects. Persistent or troublesome symptoms deserve review.

Report persistent unsteadiness, visual disturbance or troublesome sedation rather than treating them as an unavoidable price of treatment. Nausea and dizziness may be most evident during initiation or adjustment; the response to a formulation switch also deserves review.

Who needs extra care with this medicine?

Relevant exclusions include atrioventricular block, bone-marrow depression and certain porphyrias. Genetic susceptibility to serious rash matters in some ancestry groups.

Ancestry-linked HLA testing addresses a particular immune-reaction risk; it is not a test for whether the medicine will help mood or seizures. The UK label supports HLA-B*1502 screening in relevant at-risk groups but does not recommend universal HLA-A*3101 screening from the available evidence.

Can it affect my other medicines?

Many medicines interact, including hormonal contraceptives whose effectiveness can fall. Avoid grapefruit and discuss alcohol and all medicines with a pharmacist.

What check-ups will I need?

Check blood count, liver function and electrolytes before treatment. HLA-B*1502 testing is indicated for Han Chinese or Thai ancestry and considered for other at-risk groups. Sodium monitoring is intensified when risk is higher; routine levels are unnecessary for everyone.

SPS recommends an individual monitoring plan, including periodic electrolytes, liver function and vitamin D. In people with renal impairment or sodium-lowering medicines, sodium is checked after two weeks and monthly for three months, then according to need. Drug levels are useful for suspected toxicity, interactions or loss of control, rather than a compulsory routine test for everyone.

What about pregnancy, breastfeeding and age?

Pregnancy carries medicine-related risks; seek specialist advice before conception or promptly if pregnant without stopping independently. Breastfeeding may be possible with monitoring for infant sleepiness, poor feeding or jaundice.

Risks include congenital malformations such as neural-tube defects. Discuss folic acid and highly effective contraception with the team; supplementation does not remove all medicine-related risk. Carbamazepine can reduce hormonal contraceptive effectiveness, and precautions continue after stopping. The exact method and post-treatment interval need current contraceptive advice.

What if I miss a dose or want to stop?

Do not double doses. Follow the leaflet’s missed-dose advice and avoid abrupt withdrawal, particularly when treated for epilepsy.

How does it work?

Carbamazepine can reduce rapid, repeated electrical activity in nerve cells. These cells generate signals by moving electrically charged particles through tiny channels in their outer membrane. Sodium channels are one important type: they let sodium enter briefly, then need time to recover before helping generate another signal.

In laboratory studies, carbamazepine makes sustained rapid firing harder to maintain by affecting these sodium channels. They are called voltage-dependent channels because they respond to changes in electrical charge across the cell membrane. This offers part of an explanation for the medicine’s antiseizure action, but researchers have not established exactly how it produces its mood-stabilising effects.

Changing electrical activity in a nerve cell is only one step in a much larger system of communication. Bipolar disorder is not simply excessive electrical firing, and the response of a cell in an experiment cannot predict how a particular person will respond to treatment.

How does it affect my body?

Dizziness, tiredness, nausea and impaired coordination can affect activities, especially early in treatment.

Effects on alertness and coordination can be noticeable before long-term benefit is clear. Double vision, unsteadiness or marked drowsiness can also signal excessive exposure, especially after an interacting medicine is added. Avoid driving or unsafe activities when impaired and seek advice about a significant change.

How does my body process it?

CYP3A4 contributes to metabolism. Carbamazepine induces drug-metabolising enzymes, including those involved in its own clearance.

Autoinduction means that repeated carbamazepine treatment increases the activity of enzymes that clear carbamazepine itself. Exposure can therefore change during the early weeks without a simple one-to-one relationship between dose and blood concentration. Other medicines may also be cleared faster because of this enzyme induction.

How do treatment options differ?

For epilepsy, maintaining the same manufacturer’s product can matter. Oxcarbazepine has a different UK licence and is not a direct substitute.

Standard tablets, prolonged-release tablets and liquid deliver the ingredient differently. The checked prolonged-release 200/400 mg tablets are usually taken in two divided doses and must not be chewed; a prescribed half-tablet is possible. Switching requires a clear product and regimen, particularly when maintaining seizure control.

A closer look at the science

The active carbamazepine-epoxide metabolite contributes to pharmacological effects. Interactions may alter parent drug and metabolite differently.

Carbamazepine has a ring-based chemical structure and is converted to an epoxide metabolite that also has activity. Chemical similarity to another drug does not establish the same licence or an equivalent milligram dose. Parent drug and metabolite are separate substances in an interaction assessment.

How was this medicine developed?

The checked tablet information was revised in April 2026. Its historical diagnostic wording is retained with a modern explanation.

The longstanding medicine now has more detailed genetic, pregnancy and monitoring precautions than older descriptions contained. Historical familiarity is not evidence that an old dosing table or contraceptive instruction remains current.

Sources and References

  1. Tegretol 100 mg, 200 mg and 400 mg tablets — UK SmPC

    Product information published on the electronic Medicines Compendium (emc); supplied by pharmaceutical companies.

    Scope: United Kingdom product information.

  2. Tegretol tablets — UK patient leaflet

    Product information published on the electronic Medicines Compendium (emc); supplied by pharmaceutical companies.

    Scope: United Kingdom product information.

  3. Carbamazepine

    Scope: NHS.uk public information (England); not a statement of uniform services or funding across the four UK nations.

  4. Carbamazepine monitoring

    Scope: NHS Specialist Pharmacy Service (England); not a UK-wide commissioning or legal rule.

  5. Trileptal tablets — UK SmPC

    Product information published on the electronic Medicines Compendium (emc); supplied by pharmaceutical companies.

    Scope: United Kingdom product information.

  6. Tegretol 100 mg/5 mL liquid — UK SmPC

    Product information published on the electronic Medicines Compendium (emc); supplied by pharmaceutical companies.

    Scope: United Kingdom product information.

  7. Tegretol 200 mg and 400 mg prolonged-release tablets — UK SmPC

    Product information published on the electronic Medicines Compendium (emc); supplied by pharmaceutical companies.

    Scope: United Kingdom product information.

  8. Carbamazepine: current prescribing information — mechanism explanation

    Scope: Mechanism explanation only. Source sections checked: 12.1 Mechanism of Action; 12.3 Pharmacokinetics. This does not establish UK product authorisation or prescribing..

  9. McLean and Macdonald: Carbamazepine and its epoxide limit rapidly firing action potentials — mechanism explanation

    Scope: Mechanism explanation only. Source sections checked: Abstract: cultured mouse neurons and sodium-dependent action potentials. This does not establish UK product authorisation or prescribing..

  10. NIMH: Understanding psychosis

Was this article helpful?

Was this article helpful?

Sends your choice, article identifier, edition and optional issue to Psychiatry Atlas. No name, email or medical details are requested. Daily network codes help prevent spam; hosting may process technical information. This is not a promise of anonymity. Privacy details.

Enable JavaScript to send feedback.

Suggest a missing topic or describe a correction. Please keep personal medical information out of website feedback.

Back to top